Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i3-i16. doi: 10.1093/jjco/hyaf203.
ABSTRACT
BACKGROUND: In 2018, CONCORD-3 updated long-term surveillance of cancer survival trends worldwide. In this monograph, we conducted further analyses and examined trends in net survival using the Japanese data during 2000-14.
METHODS: Sixteen population-based cancer registries in Japan contributed data to CONCORD-3 with anonymized individual records on 2 237 861 patients diagnosed with one of 15 adult cancers (15-99 years), and brain tumors and hematological malignancies in children (0-14 years). Five-year net survival was estimated with the Pohar Perme estimator and age-standardized with International Cancer Survival Standard weights. We estimated survival for three calendar periods, by age group, sex, anatomic site or morphology, and by stage at diagnosis.
RESULTS: Five-year net survival improved between 2000-04 and 2010-14 for several cancers, including brain tumors (27.9%-46.3%), ovarian cancer (35.5%-46.3%), stomach cancer (50.5%-60.3%), lymphoid malignancies (47.5%-57.3%), myeloid malignancies (24.8%-33.3%), and esophageal cancer (27.7%-36.0%). Breast cancer, childhood lymphoma, and prostate cancer showed consistently high or improving survival (85.9%-93.0%). In contrast, survival for melanoma remained unchanged. Net survival was low for pancreatic cancer (6.9%-8.3%). Among selected countries, survival was higher in Japan for esophageal (36.0%), liver (30.1%), and lung cancers (32.9%). Survival for melanoma, hematologic malignancies, and childhood cancers was lower in Japan than in Western countries.
CONCLUSIONS: Net survival in Japan improved substantially for several cancers, but survival for pancreatic cancer remained low. International collaboration is crucial to accelerate the development of effective cancer control strategies.
PMID:41859880 | DOI:10.1093/jjco/hyaf203
